Abstract
The diagnosis of acute myeloblastic leukaemia (AML) is based on cell morphology, cytogenetic and molecular changes, cell markers and clinical data. Our aim was to establish whether morphology and cell markers are comparable in the evaluation of AML. Bone marrow smears were analysed, and flow cytometry and monoclonal antibodies were used to determine cell type and maturity. Morphology and cell markers correlated differently in different AML subtypes.
MeSH terms
-
Biomarkers / analysis
-
Bone Marrow Cells / chemistry
-
Bone Marrow Cells / cytology
-
Humans
-
Leukemia, Erythroblastic, Acute / classification
-
Leukemia, Erythroblastic, Acute / diagnosis
-
Leukemia, Megakaryoblastic, Acute / classification
-
Leukemia, Megakaryoblastic, Acute / diagnosis
-
Leukemia, Monocytic, Acute / classification
-
Leukemia, Monocytic, Acute / diagnosis
-
Leukemia, Myeloid, Acute / classification*
-
Leukemia, Myeloid, Acute / diagnosis
-
Leukemia, Myelomonocytic, Acute / classification
-
Leukemia, Myelomonocytic, Acute / diagnosis
-
Leukemia, Promyelocytic, Acute / classification
-
Leukemia, Promyelocytic, Acute / diagnosis